Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK presents neuroscience portfolio

GSK presents neuroscience portfolio

14th December 2007

GlaxoSmithKline (GSK) has presented an overview of its neuroscience pipeline to investors and analysts in New York this week.

The company illustrated that the portfolio now contains more than 25 compounds in clinical development spanning across 13 different diseases.

Compounds highlighted at the seminar included phase II compound 773812 for schizophrenia and 742457 for Alzheimer’s disease, with new ‘proof of concept’ data presented for each.

GSK also announced the launch of a phase II programme for ofatumumab for use in multiple sclerosis with trials starting in 2008.

The phase III treatment for compound 1838262 was profiled with the company stating its expectations to see the filing for restless leg syndrome in the third quarter of 2008, while updates for its indication in migraine prophylaxis and neuropathic pain were also announced.

Moncef Slaoui, chairman of research and development, remarked that the company was continuing to make good progress with its pipeline and that it was a key area for additional research and development investment and future growth.

“Diseases such as schizophrenia, Alzheimer’s and Parkinson’s disease present a chronic and ever expanding burden to patients, care givers and healthcare systems across the world?The urgency to provide medical solutions for this and other neurological diseases has never been greater,” Mr Slaoui said.

Also this week, GSK has presented data on the long-term safety and efficacy of its investigational drug Promacta (eltrombopag) for the treatment of chronic idiopathic thrombocytopenic purpura.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.